Danish pharma firm Lundbeck has promoted Andreas Eggert to senior VP for global product strategy and Klaus Abel to VP with responsibility for commercialisation of medicines from Lundbeck's partnership with Otsuka Pharmaceuticals.
Eggert, who joined Lundbeck in 2010 as VP for global product strategy, will have overall responsibility for the launches of several new medicines from Lundbeck during the next 18 months, including vortioxetine for major depression and Selincro (nalmefene) for alcohol dependence.
Prior to joining Lundbeck, Eggert spent several years at Wyeth (now part of Pfizer) where his roles included serving as director global strategic marketing and VP and global business manager.
Andreas Eggert and Klaus Abel
Abel's responsibilities will cover the collaborative development and commercialisation of medicines Lundbeck is working on with Otsuka as part of a multi-billion dollar deal, including a once-monthly aripiprazole formulation for the treatment of schizophrenia and brexpiprazole (OPC-34712) for the treatment of schizophrenia and major depression.
Abel, who has been with Lundbeck since 2000, and was most recently executive director with commercial responsibility for several products, will report to Eggert who will in turn report directly to president and CEO Ulf Wiinberg.